Gilead Sciences (NasdaqGS:GILD) Advances HIV Treatment With Promising Lenacapavir And Biktarvy Data
Gilead Sciences (NasdaqGS:GILD) recently experienced a significant price movement, rising 24% in the last quarter. This ...
Lawyer Monthly12d
Gilead Sciences Sets Aside $200M for HIV Drug Settlement
Gilead Sciences sets aside $200 million for a potential settlement over its HIV drug promotional speaker program amid federal ...
ETF Daily News8d
Gilead Sciences (NASDAQ:GILD) Price Target Raised to $126.00
YANKCOM Partnership purchased a new stake in shares of Gilead Sciences during the 4th quarter worth approximately $28,000. Decker Retirement Planning Inc. purchased a new stake in shares of Gilead ...
Yahoo Finance2d
Gilead Sciences, Inc. (GILD)
FOSTER CITY, Calif. & BALLERUP, Denmark, January 11, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) and LEO Pharma today announced a strategic partnership to accelerate the development and commerciali ...
Hosted on MSN25d
Deutsche Bank Upgrades Gilead Sciences (GILD)
Gilead Sciences Background Information (This description ... since the company brought its first therapies to the market. Through global partnerships, Gilead's medicines today reach millions ...
PharmiWeb23d
Gilead’s Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis
Through ground-breaking science and collaborative partnerships, the company strives to create healthier futures for everyone living with liver disease. Gilead remains devoted to a future without liver ...
Le Lézard4d
Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option
Gilead Sciences, Inc. today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment portfolio and pipeline at the Conference on Retroviruses ...
Morningstar4d
Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option
About Gilead HIV Gilead Sciences, Inc. is a biopharmaceutical ... needs of people affected by HIV around the world. Through partnerships, collaborations and charitable giving, the company also ...
Here are highlights from Tuesday’s Analyst Blog:
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including The Charles Schwab Corp., Gilead ...